Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Neurochem. 2012 Jun 7;122(2):308–320. doi: 10.1111/j.1471-4159.2012.07790.x

Figure 5.

Figure 5

Systemic administration of GBR12909 to increase endogenous DA significantly decreased both sIPSCs and mIPSCs; the effects were reversed by systemic prior administration of the GSK-3β inhibitor TDZD. A, Representative traces of the sIPSCs (left panel) and mIPSCs (right panel). B, Left panel, GBR12909 (10 mg/kg, i.p.) significantly decreased both frequency (p < 0.05) and amplitude (p < 0.01) of sIPSCs; these effects were completely blocked by TDZD (1 mg/kg, i.p.). Right panel, both frequency (p < 0.05) and amplitude (p < 0.01) of mIPSCs were significantly decreased by GBR12909 but only the amplitude was significantly prevented by TDZD.